The objective of glaucoma therapy is to preserve the patient's vision at moderate cost. Life expectancy, stage of disease and progression rate, jointly, are considered the pivotal standard of assessment of the glaucoma patient, and correct therapeutic management is fundamental.
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The objective of glaucoma therapy is to preserve the patient's vision at moderate cost. 1 It is a common perception that glaucoma has a slowly progressing pathology and that the visual function of the patient suffering from glaucoma deteriorates symptomatically only towards the terminal stage of the disease. In fact, scientific proof exists demonstrating how progression rate can be very variable from patient to patient. 2 At an unexpectedly early stage of the disease the glaucoma patient can experience such a loss of vision that his or her quality of life changes. This is reflected in an increase in accidental slips and falls 3 and road accidents 4 observed in elderly glaucoma patients compared with persons of the same age without glaucoma.
Currently, the correct clinical management and therapeutic approach for the newly diagnosed patient cannot disregard an initial assessment of the individual's lifetime risk of developing perimetric damage that will compromise quality of life.
Risk assessment is based on some fundamental elements, among which stage of pathology at the moment of diagnosis and age of the patient (and his/her life expectancy) play a primary role. The younger the patient presenting with advanced glaucoma at first diagnosis, the bigger the risk that progression of the disease will lead to serious visual impairment. By contrast, advanced age and the presence of damage at an initial stage can be considered, under this point of view, to be elements of a low risk profile.
The third and most important factor to be considered, next to age and damage stage, is the progression rate of the disease during a patient's life (see Figure 1 ). The risk of developing serious visual impairment, starting with the same age and same stage of functional damage, increases with the acceleration of disease progression. In other words, a young patient with an advanced stage of the disease but with slow progression has an overall lower risk of visual impairment than a patient of the same age and similar disease stage whose disease progression is very rapid (see Figure 2 ). A recent meta-analysis published in the Journal of Glaucoma 13 has
shown that among the drug classes mentioned above, the prostamide analogue bimatoprost has the highest ocular hypotensive efficacy (see Figure 3 ). 14 Weighted mean, fixed model
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The strong link between the amount of IOP reduction and drop in disease progression risk has recently been confirmed by the Canadian Glaucoma Study (CGS). The CGS was a multicentre, prospective, longitudinal clinical study that started with the aim of identifying ocular and systemic risk factors for the progression of perimetric damage in glaucoma. 6 In the CGS, risk factors of a cardiovascular nature, such as peripheral vasospasm, migraine or systolic and diastolic blood pressure, did not appear to be significantly associated with the progression risk of glaucomatous damage. However, every 1mmHg increase in IOP has been associated with an approximately 20% increased risk of progression.
What stands out from the trial data is that therapeutic management of the glaucoma patient needs be early and that effective prevention of increased IOP is essential, since long-term prognosis is linked to the effectiveness of therapy started at the moment of diagnosis.
If the management of patients with a middle/low-risk profile consists of choosing an effective monotherapy, the approach is different for patients with higher-risk profiles. Those with high-risk profiles include young patients with advanced damage and a fast progressing disease or those with a high probability of rapid disease progression who could require more aggressive therapies from the time of diagnosis or very early during follow-up.
The probability that two years after diagnosis a glaucoma patient needs more than one drug to decrease his or her IOP to an acceptable value based on individual risk profile has been estimated to be 75%. monotherapy. 15 The results showed that both fixed combination therapies were superior to monotherapy with beta-blockers in reducing IOP. The combination with bimatoprost was superior to the one with latanoprost. These results confirm data from the literature comparing prostaglandin analogues administrated in monotherapy. 13 These data also agree with the results of a randomised multicentre study where the efficacy of fixed combination therapies has been compared in a population of glaucoma patients previously treated with prostaglandin analogue monotherapy (see Figure 4) . 16 Although the decrease of IOP is today the only evidence-based instrument capable of altering the visual function prognosis of the patient suffering from glaucoma, it should be considered that the ultimate goal of therapeutic intervention is not IOP reduction. The goal is deceleration of disease progression rate to a level that minimises the impact of the functional deficit on the quality of life of each individual patient.
Conclusion
In conclusion, management of the glaucoma patient should be based on perimetric data, which should be considered as the best way to judge the efficacy of ocular hypotensive therapy. This should allow a more solid relationship to be built between the physician and the patient based on mutual exchange of information.
The clinician will gain information regarding the variation in disease progression rate in response to the therapeutic choice, with evident functional prognostic implications. On the patient's side, there is the potential to discuss compliance and the perception of the disease during follow-up. n
